IRX-211 Archives | Cannabiz

Nexalis suspends trial projects after funding partner withdraws support

by Steve Jones June 1, 2026June 1, 2026

Two clinical studies exploring cannabinoid therapies for breakthrough cancer pain and panic disorders have been suspended […]

News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow

by Adam Sheldon April 20, 2026June 11, 2026

Nexalis outlines 2026 plan as IRX shares jump 35%

by Adam Sheldon February 17, 2026February 19, 2026

Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent

by Adam Sheldon February 2, 2026June 8, 2026

Elixinol records first underlying operating cash flow positive quarter

by Adam Sheldon February 2, 2026February 3, 2026

InhaleRx locks in A$1m cap raise and reveals plans to rebrand

by Adam Sheldon December 1, 2025February 21, 2026

InhaleRx advances cancer pain and panic disorder trials

by Adam Sheldon July 23, 2025July 23, 2025

News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire

by Steve Jones and Martin Lane April 23, 2025April 23, 2025

News in brief: InhaleRx; Hemp Pet; Neurotech International; Cann Group

by Martin Lane November 19, 2024April 11, 2025